Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Splicing-Modulating Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLK4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLK4 Kinase Domain / Mutant Protein High purity (>90%), Endotoxin controlled. Sequence Verified. Sf9/E.coli expressed. |
View CLK4 Products |
| Gene Delivery | CLK4 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target engagement assays. |
View CLK4 Products |
| Benchmark Ab | Anti-CLK4 Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View CLK4 Products |
| Validator | CLK4 siRNA Set For target knockdown verification and RNA splicing phenotype validation. |
View CLK4 Products |
| Related Target A | CLK1 High-homology family member; essential for off-target selectivity profiling. |
View CLK1 Products |
| Related Target B | DYRK1A Dual-specificity kinase closely related in the kinome; key counter-screening target. |
View DYRK1A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against CLK1/2/3 homologs | Full panel of recombinant CLK active kinase domains available with >90% purity and verified sequences. |
| DYRK family counter-screening | High-purity DYRK1A and DYRK1B proteins strictly verified by mass spectrometry to eliminate false positives. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant controls included. |
| False Positives in Splicing Assays | Validated siRNA sets included for orthogonal target knockdown verification. |
Live CLK4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLK4 therapeutics is intensifying, with major players shifting focus from non-selective pan-kinase inhibitors to highly selective CLK1/2/4 inhibitors and splicing-modulating small molecules. As first-generation therapies reach the clinic, the next wave of R&D is targeting MYC-amplified solid tumors, triple-negative breast cancer (TNBC), and viral replication pathways where alternative splicing plays a pivotal role.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Samumed, H3 Biomedicine, Novartis | Solid Tumors (TNBC, Glioblastoma), Hematological Malignancies | Selectivity Assay (Need CLK1/2/3/4 and DYRK1A/B recombinant protein panel) |
| Splicing Modulators | Academic Consortia, Biotech Startups | Viral Infections (Influenza, HIV-1), Genetic Diseases | Cellular Target Engagement (Need Lentivirus for stable cell line generation) |
| PROTACs / Degraders | Preclinical Discovery Programs | Refractory Cancers, Drug-Resistant Tumors | Ubiquitination & Degradation Kinetics (Need high-purity protein & validation antibodies) |